Targeting the lower regions of the lung; a novel platform for pulmonary mRNA delivery

Introduction: Current strategies for lung immunotherapies are primarily targeted to the upper portions of the airways(1). Targeted delivery to the lower regions of the lung is necessary for treatment of parenchymal lung injury, however, delivery is challenging, which limits current clinical usage(2). Recently, lipid delivery of mRNA has proven essential in the success of the COVID-19 vaccine(3). But, strict delivery of mRNA to the lung has been less effective. Here, we explore the use of one-component multifunctional sequence-defined ionizable amphiphilic Janus dendrimers (IAJD) to deliver mRNA to the lung.